WEBER EFFECT: AN EXTENDED ANALYSIS FOR TEN YEARS OF REPORTING TRENDS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

被引：6
|
作者：
Beulah, E. [1 ]
Reddy, N. [2 ]
Subeesh, V [3 ]
Maheswari, E. [3 ]
Pudi, C. [3 ]
机构：
[1] MS Ramaiah Univ Appl Sci, Bengalore, India
[2] Ramaiah Univ Appl Sci, Bangalore, Karnataka, India
[3] MS Ramaiah Univ Appl Sci, Bangalore, Karnataka, India
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2200
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM79
引用
收藏
页码：S369 / S369
页数：1
相关论文
共 50 条
  • [31] A Real-World Safety Analysis of Upadacitinib Based on FDA Adverse Event Reporting System (FAERS)
    Zhao, Yazheng
    Cheng, Qian
    Zou, Shupeng
    Shi, Xuan
    Ouyang, Mengling
    Sun, Minghui
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2023, 2023
  • [32] Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Dai, Zhicheng
    Zhang, Jiafeng
    Tao, Zhengbo
    Gao, Rui
    Zhao, Qinghua
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [33] Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS)
    Shi, Fang-e
    Yu, Zhe
    Sun, Chengyue
    Gao, Peiliang
    Zhang, Haiyan
    Zhu, Jihong
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (02) : 221 - 229
  • [34] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
    Jow, Steven
    Hutfless, Susan
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
  • [35] Indication and adverse event profiles of denosumab and zoledronic acid: based on US FDA adverse event reporting system (FAERS)
    Su, Si
    Wu, Liuqing
    Zhou, Guibao
    Peng, Lingling
    Zhao, Huanzhe
    Wang, Xiao
    Li, Kuan
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [36] Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS)
    Wittayanukorn, Saranrat
    Qian, Jingjing
    Johnson, Brandon S.
    Hansen, Richard A.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (02) : 93 - 102
  • [37] Pediatric drug-induced anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS)
    Brameli, Anna
    Yuan, Irene H.
    Phillips, Elizabeth J.
    Stone Jr, Cosby A.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (09):
  • [38] A Review of Drug Reaction with Eosinophilia and Systemic Symptoms in the FDA Adverse Event Reporting System FAERS)
    Bluestein, Sara
    Yu, Roger
    Stone, Cosby
    Phillips, Elizabeth
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB12 - AB12
  • [39] A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins
    Huiling Su
    Jing Jia
    Yuxiang Mao
    Riran Zhu
    Zhengjun Li
    [J]. Scientific Reports, 14
  • [40] Time to onset analysis of letrozole associated osteonecrosis of jaw in FDA adverse event reporting system (FAERS) database
    Viswam, Subeesh Kulangara
    Reddy, Neha
    Gouri, Nair
    Sai, Minnikanti Satya
    Kunnavil, Radhika
    Maheswari, Eswaran
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 460 - 460
12345